Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com
Investment analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance AKTX stock opened at $3.48 on Tuesday. Akari Therapeutics has a 52 week low of […]
More Stories
EBay Turns Down GameStop’s $55.5 Billion Takeover Proposal
By Andrew Moran EBay has turned down videogame retailer GameStop’s $55.5 billion takeover proposal. The online marketplace, in a May...
Trump Nominates Lake, Mastriano to Diplomatic Posts
By Kimberly Hayek President Donald Trump on Monday announced a slew of nominations sent to the U.S. Senate, including two...
Treasury Department Alerts US Banks to Suspected Iranian Money Laundering Efforts
By Victoria Friedman The U.S. Treasury Department’s Financial Crimes Enforcement Network (FinCEN) on May 11 issued an alert to financial...
Gas Prices Lift US Annual Inflation Rate to 3.8 Percent Highest Since May 2023
By Andrew Moran Consumer prices accelerated for the second straight month in April as the war in Iran added to...
Canadians Increasingly Favor Economic Growth Over Environmental Stewardship in Energy Policy: Poll
By William Hetherington Canadians are increasingly prioritizing economic growth over environmental protection in energy policy decisions, with support for new...
Record 45 Million Americans Expected to Travel Over Memorial Day Weekend: AAA
By Mary Prenon Despite rising gas prices, more than 45 million Americans are expected to hit the road, fly, or...